ARCHIVES

The 99th turned Out Well For Cancer Program, But Several Important Issues Await 100th Congress

This article is from The Cancer Letter archive.

Vol. 12 No. 42 | October 31, 1986

Download PDF Visit The Full Archive

Related Articles

Tamoxifin Benefits Outweigh Risks, NSABP Study Finds

March 23, 1994

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

NCI/DCT Advisors Approve Concept For $15 Million Lymphoma Studies

June 15, 1990

NCI To Pilot Text Chat On CancerNet And CIS Sites.

September 29, 2000

In Brief: ACS Board Names McGinnis Prsident; Fuller Re-Elected chairman; Lenhard Is Vice President

November 25, 1994

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007